SLS / SELLAS Life Sciences to Participate in Upcoming Conferences in October 2021

NEW YORK, Oct. 17, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical b more_horizontal

NEW YORK, Sept. 18, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the “Company”), a late-stage clinical bio more_horizontal

NEW YORK, May 25, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical b more_horizontal

Sellas Life Sciences Group Inc. SLS, -3.40% said Friday that it raised $20.0 million, through the public sale of common shares and warrants to buy sto more_horizontal

SELLAS Life Sciences (NASDAQ: SLS ) stock is falling on Friday after the late-stage clinical biopharmaceutical company announced a proposed public off more_horizontal

GenFleet Therapeutics has granted GFH009 rights to SELLAS Life Sciences Group Inc (NASDAQ: SLS) across all therapeutic and diagnostic uses worldwi more_horizontal

NEW YORK, Oct. 07, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the “Company”), a late-stage clinical bio more_horizontal

NEW YORK, Oct. 07, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the “Company”), a late-stage clinical bio more_horizontal